Atorvastatin in episodic migraine
Key facts
- Where
- Bergen, Lørenskog, Oslo, Tromsø és Trondheim, NorvégiaSee the 5 sites
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Norvégia
- Helse Bergen HFBergen, NorvégiaTaking people
- Akershus University HospitalLørenskog, NorvégiaTaking people
- Oslo University Hospital HFOslo, NorvégiaTaking people
- Universitetssykehuset Nord-NorgeTromsø, NorvégiaTaking people
- St. Olavs hospital HFTrondheim, NorvégiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Olavs Hospital HF
- Trial code
- EU 2022-502176-23-01
- Record updated
- 2026. április 14.
- Original description
To evaluate whether the favourable preventative effect ofAtorvastin in two different doses seen in three smaller studies, can be confirmed in a larger multicentre randomized, controlled studyRead full original descriptionShow less
A multicentre, triple blind, placebo controlled, parallel group study of atorvastatin in episodic migraine (StatinMigEpisodic)
To evaluate whether the favourable preventative effect ofAtorvastin in two different doses seen in three smaller studies, can be confirmed in a larger multicentre randomized, controlled study
Inclusion: Aged 18 to 65 years with 4-14 migraine days per month; Signed informed consent; Episodic migraine with or without aura according to ICHD-3 criteria, debut of migraine at least one year prior to inclusion, and start of migraine before age 50 years; No use of other migraine prophylactics during the study; For women of child-bearing potential there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception.
Exclusion: Interval headache not distinguishable from migraine or chronic migraine, chronic tension-type headache, medication overuse headache or other headache occurring on ≥ 15 days/month; Hypersensitivity to statins or previous use of statins; Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study; Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years; Consistently failing to respond to any acute migraine medication and/or requiring detoxification from acute medication (triptans, opioids); Clinical information on signs of cholestasis, decreased hepatic or renal function, high degree of comorbidity, frailty associated with reduced life expectancy, high likelihood of hospitalization at the discretion of the investigator,, history of angioneurotic oedema, current use of antiviral treatment against hepatitis C, significant psychiatric illness, alcohol or illicit drug dependence, inability to understand study procedures and to comply with them for the entire length of the study, and/or treatment for hypothyroidism; Pregnancy, planning to get pregnant, inability to use contraceptives or lactating.